<DOC>
	<DOCNO>NCT02903524</DOCNO>
	<brief_summary>Evaluate efficacy safety Doxorubicin Hydrochloride Liposome Injection Plus Cyclophosphamide Compared Pirarubicin Plus Cyclophosphamide Neoadjuvant Chemotherapy Locally Advanced Breast Cancer Patients</brief_summary>
	<brief_title>Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide v Pirarubicin Combination With Cyclophosphamide Patients With Locally Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pirarubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Female patient age 18 70 year . Newly diagnose breast cancer , stag IIbIIIc . KPS performance status≥70 . Measurable disease accord RECIST version 1.1 . Normal cardiac function confirm baseline leave ventricular ejection fraction ( LVEF ) ≥50 % . Adequate bone marrow reserve ( WBC≥4.0×10 ( 9 ) /L , neutrophils≥2.0×10 ( 9 ) /L , platelets≥100×10 ( 9 ) /L , hemoglobin≥90g/L ) . Adequate hepatic renal function . AST ALT ≤ 2×institutional upper limit normal；alkaline phosphatase ≤ 2×institutional upper limit normal；bilirubin ≤ institutional upper limit normal . Serum creatinine≥44 µmol/L ≤133 µmol/L . Written inform consent acquire . Not pregnancy pregnancy test females negative . Severe heart failure ( NYHA grade II high ) . Active uncontrolled severe infection . Have accept antitumor drug within 30 day first dose receive radiation treatment . Other situation investigator consider contraindication study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>